The Foundation for AIDS Research has warned that the Trans-Pacific Partnership’s changes to IP policy could restrict access to affordable generic medicines in low and middle income countries.
Japanese drug maker Otsuka Holdings has agreed to buy Avanir Pharmaceuticals as part of a multi-billion dollar deal that could ease its potential patent woes.
Criminal gangs in Australia are branching away from traditional forms of counterfeiting and are targeting pharmaceuticals, an Australian customs official has revealed.
Indian drug maker Cipla has signed a deal with Salix Pharmaceuticals allowing the US-based company exclusive rights relating to the Rifaximin Complexes patent family.
The Australian government department responsible for IP has suggested abolishing a committee that looks after plant breeders’ rights as it looks at alternative means for giving advice to breeders.
Companies in Australia will be able to continue to patent human genes after a court rejected an appeal by a breast cancer survivor.
A group of 12 international biotechnology associations has written to the US Patent and Trademark Office (USPTO), raising concerns about the office’s guidelines on determining the patent eligibility of natural products in the aftermath of the Myriad and Mayo cases.
Australian biotechnology company NeuClone has signed an agreement with vaccine maker the Serum Institute of India to manufacture and supply ten biosimilar monoclonal antibody drugs around the world.
Personal health records company MMR Global has entered into a licensing agreement with Australian medical database company Claydata.
Stem cell research companies in Canada and Australia have teamed up to support increased research and development in both countries.